Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats

Journal of Thoracic and Cardiovascular Surgery

Volumn 128, Issue 6, 2004, Pages 850-859

  Lu, Jun ^a   Shimpo, Hideto ^a   Shimamoto, Akira ^a,b   Chong, Albert J ^b   Hampton, Craig R ^b   Spring, Denise J ^b   Yada, Masaki ^a   Takao, Motoshi ^a   Onoda, Koji ^a   Yada, Isao ^a   Pohlman, Timothy H ^b   Verrier, Edward D ^b  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; CYTOKINE; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; BODY WEIGHT; CELL COUNT; CELL PROLIFERATION; CONTROL GROUP; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL RAT; HISTOPATHOLOGY; INFLAMMATION; LUNG; LUNG ARTERY PRESSURE; MACROPHAGE; MALE; MEASUREMENT; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RADIATION INJURY; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MONOCROTALINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 9644265110     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2004.03.003     Document Type: Article

References (41)

1. Rubin L.J. Primary pulmonary hypertension. N Engl J Med. 336:1997;111-117
2. Meyrick B., Gamble W., Reid L. Development of Crotalaria pulmonary hypertension hemodynamic and structural study. Am J Physiol. 239:1980;H692-702
3. Lee S.D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 101:1998;927-934
4. Tuder R.M., Groves B., Badesch D.B., Voelkel N.F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 144:1994;275-285
5. Humbert M., Monti G., Brenot F., Sitbon O., Portier A., Grangeot-Keros L., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 151:1995;1628-1631
6. Yeager M.E., Halley G.R., Golpon H.A., Voelkel N.F., Tuder R.M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res. 88:2001;E2-11
7. Voelkel N.F., Tuder R.M., Bridges J., Arend W.P. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol. 11:1994;664-675
8. Herlaar E., Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today. 5:1999;439-447
9. Stewart A.G. Airway wall remodelling and hyperresponsiveness modelling remodelling in vitro and in vivo. Pulm Pharmacol Ther. 14:2001;255-265
10. Sugden P.H., Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 83:1998;345-352
11. Welsh D.J., Peacock A.J., MacLean M., Harnett M. Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. Am J Respir Crit Care Med. 164:2001;282-289
12. Jin N., Hatton N., Swartz D.R., Xia X., Harrington M.A., Larsen S.H., et al. Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol. 23:2000;593-601
13. Takahashi S., Keto Y., Fujita T., Uchiyama T., Yamamoto A. FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. J Pharmacol Exp Ther. 296:2001;48-56
14. Borgermann J., Friedrich I., Flohe S., Spillner J., Majetschak M., Kuss O., et al. Tumor necrosis factor-alpha production in whole blood after cardiopulmonary bypass downregulation caused by circulating cytokine-inhibitory activities. J Thorac Cardiovasc Surg. 124:2002;608-617
15. Feeser W, Freimark BD [database online]. Nucleotide sequence of rat prointerleukin-1 beta mRNA. GenBank database. 1992. http://www.ncbi.nlm.nih.gov: 80/entrez/viewer.fcgi?db=nucleotide&val=204905
16. Yoshimura T., Takeya M., Takahashi K. Molecular cloning of rat monocyte chemoattractant protein-1 (MCP-1) and its expression in rat spleen cells and tumor cell lines. Biochem Biophys Res Commun. 174:1991;504-509
17. Fort P., Marty L., Piechaczyk M., el Sabrouty S., Dani C., Jeanteur P., et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 13:1985;1431-1442
18. Mitani Y., Maruyama K., Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation. 96:1997;689-697
19. Dorfmuller P., Zarka V., Durand-Gasselin I., Monti G., Balabanian K., Garcia G., et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 165:2002;534-539
20. Karmochkine M., Wechsler B., Godeau P., Brenot F., Jagot J.L., Simonneau G. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis. 55:1996;561-562
21. Bellotto F., Chiavacci P., Laveder F., Angelini A., Thiene G., Marcolongo R. Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax. 54:1999;372-374
22. Voelkel N.F., Cool C., Lee S.D., Wright L., Geraci M.W., Tuder R.M. Primary pulmonary hypertension between inflammation and cancer. Chest. 114:(suppl):1998;225S-230S
23. Olschewski H., Rose F., Grunig E., Ghofrani H.A., Walmrath D., Schulz R., et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med. 138:2001;367-377
24. Behr T.M., Berova M., Doe C.P., Ju H., Angermann C.E., Boehm J., et al. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr Opin Investig Drugs. 4:2003;1059-1064
25. Stenmark K.R., Morganroth M.L., Remigio L.K., Voelkel N.F., Murphy R.C., Henson P.M., et al. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am J Physiol. 248:1985;H859-866
26. Todorovich-Hunter L., Johnson D.J., Ranger P., Keeley F.W., Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study. Lab Invest. 58:1988;184-195
27. Wilson D.W., Segall H.J., Pan L.C., Lame M.W., Estep J.E., Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 22:1992;307-325
28. Sugita T., Hyers T.M., Dauber I.M., Wagner W.W., McMurtry I.F., Reeves J.T. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol. 54:1983;371-374
29. Miyata M., Sakuma F., Yoshimura A., Ishikawa H., Nishimaki T., Kasukawa R. Pulmonary hypertension in rats. 2. Role of interleukin-6. Int Arch Allergy Immunol. 108:1995;287-291
30. Kimura H., Kasahara Y., Kurosu K., Sugito K., Takiguchi Y., Terai M., et al. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest. 78:1998;571-581
31. Ikeda Y., Yonemitsu Y., Kataoka C., Kitamoto S., Yamaoka T., Nishida K., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 283:2002;H2021-2028
32. Wang M., Sankula R., Tsai B.M., Meldrum K.K., Turrentine M., March K.L., et al. P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression. Shock. 21:2004;170-174
33. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:1994;739-746
34. Li C., Hu Y., Mayr M., Xu Q. Cyclic strain stress-induced mitogen-activated protein kinase (MAPK) phosphatase 1 expression in vascular smooth muscle cells is regulated by Ras/Rac-MAPK pathways. J Biol Chem. 274:1999;25273-25280
35. McMurtry I.F., Bauer N.R., Fagan K.A., Nagaoka T., Gebb S.A., Oka M. Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv Exp Med Biol. 543:2003;127-137
36. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 47:2000;185-201
37. Song C.H., Lee J.S., Lee S.H., Lim K., Kim H.J., Park J.K., et al. Role of mitogen-activated protein kinase pathways in the production of tumor necrosis factor-alpha, interleukin-10, and monocyte chemotactic protein-1 by Mycobacterium tuberculosis H37Rv-infected human monocytes. J Clin Immunol. 23:2003;194-201
38. Roth R.A., Reindel J.F. Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. Adv Exp Med Biol. 283:1991;477-487
39. Valdivia E., Sonnad J., Hayashi Y., Lalich J.J. Experimental interstitial pulmonary edema. Angiology. 18:1967;378-383
40. Borsch-Haubold A.G., Pasquet S., Watson S.P. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem. 273:1998;28766-28772
41. Clerk A., Sugden P.H. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett. 426:1998;93-96